This expansion has been especially prominent in the field of multiple myeloma, a cancer of plasma cells, where researchers have identified B-cell maturation antigen (BCMA) as a highly promising therapeutic target due to its consistent expression on malignant plasma cells and limited presence on normal tissues (20, 21). This evidence concerns the gene TNFRSF17 and plasma cell myeloma.